Ubie
Japan's AI symptom checker — 20 questions, 3 minutes, no signup
Overview
Ubie is a free, registration-free AI symptom checker from Tokyo: roughly 20 adaptive questions in about three minutes produce a report on likely causes, recommended specialists, and urgency, drawing on 50,000+ peer-reviewed papers and a panel of 50+ medical advisors.
Pricing
Pricing shown for reference only. These figures reflect RECATOOLS research as of 31 Aug 2026 and may be out of date or incomplete. This is not financial or purchasing advice — always confirm the current price on the provider’s official website before making any decision.
- Possible causes ranked by symptom answers
- Severity and care-urgency guidance
- Available 24/7 on web and mobile
- Converts site visitors into appointments
- Pre-visit symptom intake
- Quote via Ubie sales
- Patient-finding for underdiagnosed conditions
- Custom enterprise contracts
Use cases
What you can produce with Ubie
- Personalised symptom report listing ranked possible disease candidates within 3 minutes
- Guidance on which medical specialist to consult and estimated urgency level
- Plain-language disease information drawn from peer-reviewed publications
- Doctor's Note: written Q&A response from a medical professional (paid add-on)
- Ubie Medical Navigator: AI-generated pre-consultation intake notes for hospital staff
- Disease-awareness content channel for pharmaceutical partners (Ubie for Pharma)
- Integration with NTT Docomo d Account for personalised health guidance (Japan, 2025)
ASEAN Perspective
Ubie in Southeast Asia
Ubie opened a Singapore office in 2020 and positions it as an APAC hub, but the product's deep clinical integration — EMR links, hospital workflow tools, Japanese-language UX optimisations for elderly users — is firmly rooted in Japan. No confirmed country-specific rollouts exist for Indonesia, Malaysia, the Philippines, Thailand, or Vietnam as of mid-2026. The NTT Docomo alliance (March 2025) integrates Ubie with 100M+ Japanese d-Account holders, reinforcing Japan-first momentum. ASEAN users can access the English-language symptom checker at ubiehealth.com, but without localised disease prevalence data or regional regulatory clearances the tool's utility in Southeast Asia remains that of a general global product, not a regionally tailored one.
Ubie clears a bar most AI symptom checkers don't bother with: published, peer-reviewed accuracy data. A 2024 medRxiv vignette study put its top-10 diagnostic hit rate at 71.6%, close to the 72.9% median for physicians on the same cases. The consumer product backs that up with genuine frictionlessness — free, no account, three minutes on a phone — and the company's B2B arm, Medical Navigator, is used by 1,800+ Japanese hospitals and clinics, with a Mayo Clinic collaboration announced in February 2026.
Reach outside Japan is thinner than the funding numbers suggest. The US product has grown fast (organic users up 85% since 2024) but is still a fraction of the Japan business, and ASEAN coverage beyond a Singapore office isn't documented. No public API. Results are guidance, not diagnosis — a distinction the product states clearly but some users miss.
What people say
71.6% — that is the top-10 diagnostic accuracy Ubie posted in an independent medRxiv vignette study published in 2024, against a median physician score of 72.9% on the same 328 test cases, and ahead of the rival checkers in the comparison. It is one of the only AI symptom checkers with published, peer-reviewed numbers behind it rather than marketing claims, and it is a large part of why Ubie became the default consumer symptom checker in Japan.
The product is straightforward: around 20 adaptive, doctor-written questions, roughly three minutes, no account required, and a report covering 1,100+ possible conditions with a recommended specialist type and an urgency level — grounded in 50,000-plus peer-reviewed papers and continuously reviewed by a panel of 50-plus medical specialists. Thirteen million people use it monthly, two million of them in the US, growing at roughly 25% month on month.
The B2B side is the quieter half of the business. Ubie Medical Navigator handles patient intake and documentation at 1,800+ Japanese hospitals and clinics, and Ubie for Pharma serves 21 of the top 30 global life-sciences companies with patient-funnel and disease-awareness analytics. A February 2026 collaboration with Mayo Clinic on Smart Support, a unified digital front door, followed a 30-week pilot inside Mayo's Platform Accelerate programme and signals a real push into US health-system infrastructure.
The gaps are mostly geographic and structural. The US consumer product is growing quickly but still trails Japan by a wide margin, and despite a Singapore office open since 2020 the care-routing and clinic data stay US- and Japan-centric — Malaysia, Indonesia and the Philippines get little localised coverage. There is no public developer API, so integration outside Ubie's own closed-contract partnerships is not an option. And, as with any symptom checker, the output is guidance on what to ask a doctor about, not a diagnosis, however good the accuracy numbers look on paper.
Summary of public user & expert reviews, compiled by RECATOOLS.
Notable facts
- Ubie's co-founder Dr. Yoshinori Abe was practising medicine when he realised doctors in Japan spend up to two hours on paperwork for every one hour with a patient — that frustration became the company's founding mission.
- An independent 2024 medRxiv study found Ubie's top-10 diagnostic accuracy (71.6%) is within one percentage point of the median physician score (72.9%) on the same clinical vignettes.
- As part of its March 2025 alliance with NTT Docomo, Ubie's symptom checker is being integrated with Docomo's 'd Account' ecosystem — giving it potential reach into over 100 million Japanese mobile subscribers.
- Ubie designed its early Japanese-market UI to resemble karaoke remote controls and ATM buttons, recognising that many elderly patients were unfamiliar with modern smartphone interfaces.
Frequently asked questions
About this listing
This entry was compiled from publicly available data including Ubie's official website, press releases, documentation, and reputable third-party publications. RECATOOLS is not affiliated with Ubie unless explicitly stated.
Third-party AI tools update their pricing, features, availability, and policies frequently. Information here may be outdated by the time you read this — we make reasonable efforts to keep listings current, but cannot guarantee absolute accuracy.
For the latest details, please refer to Ubie directly →
Spotted something out of date? Suggest an update →
More in Healthcare
